Florian Ingelfinger

Florian Ingelfinger

Auto-generated profile, based on publicly available information

Florian Ingelfinger

Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Nature Aging
Verified
Journal Article
Open access
PDF file
SKSinduya Krishnarajah
Sinduya Krishnarajah
FIFlorian Ingelfinger
Florian Ingelfinger
EFEkaterina Friebel
Ekaterina Friebel
DCDilay Cansever
Dilay Cansever
AAAna Amorim
Ana Amorim
BBBurkhard Becher
Burkhard Becher
Aging exerts profound and paradoxical effects on the immune system, at once impairing proliferation, cytotoxicity and phagocytosis, and inducing chronic inflammation. Previous studies have focused on individual tissues or cell types, while a comprehensive multisystem study of tissue-resident and circulating immune populations during aging is lacking. Here we reveal an atlas of age-related changes in the abundance and phenotype of immune cell populations across 12 mouse tissues. Using cytometry-based high parametric analysis of 37 mass-cytometry and 55 spectral flow-cytometry parameters, mapping samples from young and aged animals revealed conserved and tissue-type-specific patterns of both immune atrophy and expansion. We uncovered clear phenotypic changes in both lymphoid and myeloid lineages in aged mice, and in particular a contraction in natural killer cells and plasmacytoid dendritic cells. These changes correlated with a skewing towards myelopoiesis at the expense of early lymphocyte genesis in aged mice. Taken together, this atlas represents a comprehensive, systematic and thorough resource of the age-dependent alterations of the mammalian immune system in lymphoid, barrier and solid tissues.

13 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BMBruno Marcel Silva de Melo
Bruno Marcel Silva de Melo
FVFlávio Protásio Veras
Flávio Protásio Veras
PZPascale Zwicky
Pascale Zwicky
DLDiógenes Lima
Diógenes Lima
FIFlorian Ingelfinger
Florian Ingelfinger
JAJose C. Alves-Filho
Jose C. Alves-Filho

18 February 2025 in European Journal of Immunology
Verified
Journal Article
Open access
ARAvital Rodov
Avital Rodov
HBHosna Baniadam
Hosna Baniadam
RZRobert Zeiser
Robert Zeiser
IAIdo Amit
Ido Amit
NYNir Yosef
Nir Yosef
FIFlorian Ingelfinger
Florian Ingelfinger
Recent advances in multi‐omics and spatially resolved single‐cell technologies have revolutionised our ability to profile millions of cellular states, offering unprecedented opportunities to understand the complex molecular landscapes of human tissues in both health and disease. These developments hold immense potential for precision medicine, particularly in the rational design of novel therapeutics for treating inflammatory and autoimmune diseases. However, the vast, high‐dimensional data generated by these technologies present significant analytical challenges, such as distinguishing technical variation from biological variation or defining relevant questions that leverage the added spatial dimension to improve our understanding of tissue organisation. Generative artificial intelligence (AI), specifically variational autoencoder‐ or transformer‐based latent variable models, provides a powerful and flexible approach to addressing these challenges. These models make inferences about a cell's intrinsic state by effectively identifying complex patterns, reducing data dimensionality and modelling the biological variability in single‐cell datasets. This review explores the current landscape of single‐cell and spatial multi‐omics technologies, the application of generative AI in data analysis and modelling and their transformative impact on our understanding of autoimmune diseases. By combining spatial and single‐cell data with advanced AI methodologies, we highlight novel insights into the pathogenesis of autoimmune disorders and outline future directions for leveraging these technologies to achieve the goal of AI‐powered personalised medicine.

10 October 2025 in Cancer Research
Verified
Journal Article
Closed access
AGAnna Gurevich-Shapiro
Anna Gurevich-Shapiro
PZPascale Zwicky
Pascale Zwicky
EWEitan Winter
Eitan Winter
MZMor Zada
Mor Zada
NSNoam Shapira
Noam Shapira
IAIdo Amit
Ido Amit
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for relapsed/refractory B-cell malignancies. Despite its success, approximately 60% of patients experience treatment failure, underscoring the need to better understand the determinants of response and resistance. We performed single-cell RNA sequencing of pretreatment peripheral blood samples and anti-CD19 CAR T-cell products from 57 diffuse large B-cell lymphomas (DLBCL), correlating molecular and cellular features with clinical outcomes. At the time of leukapheresis, responders presented elevated levels of CD16+ monocytes and CD4+ effector memory T cells. In contrast, nonresponders showed an inflammation-driven gene expression signature across T-cell and myeloid compartments, marked by upregulation of TNFα response signaling pathways. Notably, the presence of malignant or healthy B cells (13 of 57 patients) was strongly associated with a favorable response. These findings shed light on the immune landscape conducive to successful CAR T-cell therapy and offer a molecular framework for developing personalized tools to improve patient selection, stratification, and the design of next-generation CAR T-cell treatments. Significance: Single-cell analysis of pretreatment peripheral blood from diffuse large B-cell lymphoma identified immune cell populations and genetic signatures correlated with CAR T-cell outcomes, informing patient selection, treatment strategies, and next-generation CAR T development.

22 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
TNTradite Neziraj
Tradite Neziraj
EPElisabeth Pössnecker
Elisabeth Pössnecker
AWAngela A. Wang
Angela A. Wang
PSPaul Saary
Paul Saary
ASAdrian-Minh Schumacher
Adrian-Minh Schumacher
APAnne-Katrin Pröbstel
Anne-Katrin Pröbstel
Therapy with anti-CD20 monoclonal antibodies is highly efficacious in various autoimmune diseases including multiple sclerosis (MS), a prototypic autoimmune inflammatory disease of the central nervous system (CNS). However, which B cell subsets and altered B cell–regulating factors mediate the clinical efficacy of anti-CD20 treatment is unclear. To address this gap in knowledge, we performed longitudinal high-dimensional single-cell transcriptomic and proteomic profiling of blood, cerebrospinal fluid (CSF), and intestinal samples from people with MS (pwMS), combined with immune profiling in a preclinical autoimmune encephalomyelitis model during anti-CD20 therapy. CSF analyses were performed using previously published datasets. Multisite intestinal profiling was conducted in one anti-CD20–treated patient with MS and one control participant. By applying algorithm-guided analyses of flow cytometry, single-cell transcriptomic, and immune receptor repertoire data, we found that anti-CD20 B cell depletion was associated with increased frequencies of regulatory mucosal-derived IgA-producing B cells in the periphery and CSF, together with increased B cell receptor clonal overlap between mucosal and systemic compartments, indicating enhanced trafficking of IgA B cells from gut mucosal tissues to the systemic circulation and the CNS. Moreover, we demonstrated that higher levels of B cell–activating factor and a proliferation-inducing ligand were related to favorable outcomes in pwMS during anti-CD20 treatment. Together, our findings suggest that mucosal immune regulatory mechanisms may be harnessed by anti-CD20 B cell depletion, opening previously unknown therapeutic avenues for MS.

22 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JVJuan Villar-Vesga
Juan Villar-Vesga
DFDonatella De Feo
Donatella De Feo
PCPauline Clément
Pauline Clément
FIFlorian Ingelfinger
Florian Ingelfinger
CUCan Ulutekin
Can Ulutekin
SMSarah Mundt
Sarah Mundt
Multiple sclerosis (MS) is characterized by neuroinflammation, oxidative stress, iron toxicity and mitochondrial dysfunction. Reactive oxygen species (ROS) produced by mononuclear phagocytes (MPs) are widely held to drive tissue damage, yet the specific roles of central nervous system (CNS)- resident versus CNS-invading MPs remain unclear. Here, by combining single-cell profiling with conditional gene targeting, we systematically dissected and interfered with ROS production across CNS MPs in a preclinical model for neuroinflammation. We show that CNS-invading monocyte derived cells (MdCs) exhibit a higher oxidative stress gene signature and produce more ROS compared to CNS-resident microglia. While NADPH oxidase 2 (NOX2), a phagocytic source of ROS, proved redundant, our findings underscore the critical role of mitochondrial ROS (mtROS) in driving oxidative tissue damage. Quenching mtROS through mitocatalase overexpression in MdCs, but not microglia, significantly alleviated neuroinflammation in mice. Thus, our study resolves a longstanding controversy, identifying MdCs as the primary driver of ROS-mediated neuropathology.